Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) posted its earnings results on Thursday. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.44, Zacks reports.
Monopar Therapeutics Stock Performance
Shares of MNPR traded down $1.32 during mid-day trading on Thursday, reaching $60.12. The stock had a trading volume of 442,941 shares, compared to its average volume of 225,041. The business has a fifty day moving average of $56.71 and a 200 day moving average of $66.01. The firm has a market cap of $402.72 million, a price-to-earnings ratio of -33.27 and a beta of 1.49. Monopar Therapeutics has a 12 month low of $28.40 and a 12 month high of $105.00.
Wall Street Analysts Forecast Growth
MNPR has been the subject of a number of research reports. Wall Street Zen upgraded shares of Monopar Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. BTIG Research reissued a “buy” rating and issued a $104.00 target price on shares of Monopar Therapeutics in a report on Monday, February 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, January 21st. Chardan Capital restated a “buy” rating and set a $100.00 target price on shares of Monopar Therapeutics in a research report on Monday, March 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $107.00.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. purchased a new position in shares of Monopar Therapeutics in the third quarter valued at about $28,000. BNP Paribas Financial Markets boosted its stake in Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after purchasing an additional 349 shares during the period. Meeder Asset Management Inc. bought a new position in Monopar Therapeutics in the 4th quarter worth approximately $65,000. JPMorgan Chase & Co. grew its holdings in Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after buying an additional 1,821 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Monopar Therapeutics during the second quarter valued at approximately $80,000. Institutional investors own 1.83% of the company’s stock.
Monopar Therapeutics Company Profile
Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.
The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.
Featured Stories
- Five stocks we like better than Monopar Therapeutics
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
